KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary.

The Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) represents the first KDIGO guideline on this subject. Its scope includes nomenclature, diagnosis, prognosis, and prevalence; kidney manifestations; chronic kidney disease (CKD) management and progression, kidney failure, and kidney replacement therapy; therapies to delay progression of kidney disease; polycystic liver disease; intracranial aneurysms and other extrarenal manifestations; lifestyle and psychosocial aspects; pregnancy and reproductive issues; pediatric issues; and approaches to the management of people with ADPKD. The guideline has been developed with patient partners, clinicians, and researchers around the world, with the goal to generate a useful resource for healthcare providers and patients by providing actionable recommendations.

Vaginal Antiseptic Preparation at the Time of Hysterectomy: A Systematic Review and Meta-Analysis.

Objective: To compare the rates of surgical site infection (SSI) after hysterectomy using vaginal antisepsis with chlorhexidine gluconate (CHG) versus povidone-iodine (PI).

Data Sources: PubMed, Embase, and Clinicaltrials.gov databases were queried from January 1, 1985 through Dec 7, 2023.

Incorporating Economic Evidence in Clinical Guidelines: A Framework From the Clinical Guidelines Committee of the American College of Physicians.

In recognition of accelerating health care spending and alignment with the American College of Physicians (ACP) principles of promoting high-value care, the ACP Clinical Guidelines Committee (CGC) developed a framework to standardize its approach to identifying, appraising, and considering economic evidence in the development of ACP clinical guidelines. This article presents the CGC's process for incorporating economic evidence, which encompasses cost-effectiveness analyses, economic outcomes in randomized controlled trials, and resource utilization (intervention cost) data. Economic evidence is one component of ACP recommendations.

Treatment of Obsessive-Compulsive Disorder in Children and Youth: A Meta-Analysis.

Context: Treatments for obsessive-compulsive disorder (OCD) in children and adolescents.

Objective: Evaluate the comparative efficacy of behavioral and pharmacologic treatments.

Data Sources: Six databases and ClinicalTrials.

Brief Assessment Tools for Obsessive Compulsive Disorders in Children: A Systematic Review.

Context: Children and adolescents with suspected obsessive-compulsive disorder (OCD).

Objective: To estimate the comparative performance of brief diagnostic assessment tools.

Data Sources: PubMed, the Cochrane Register of Clinical Trials, the Cochrane Database of Systematic Reviews, Embase, CINAHL, PsycINFO, and ERIC, and for unpublished studies with reported results in ClinicalTrials.